TScan Therapeutics, Inc.

TCRX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$127-$89-$66-$49
Dep. & Amort.$4$5$5$3
Deferred Tax$0$0$0-$9
Stock-Based Comp.$10$5$5$3
Change in WC$5$18-$10-$6
Other Non-Cash-$2-$0$0$9
Operating Cash Flow-$111-$61-$67-$49
Investing Activities
PP&E Inv.-$4-$3-$4-$10
Net Acquisitions$0$0$0$0
Inv. Purchases-$241-$78$0$0
Inv. Sales/Matur.$193$20$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$53-$61-$4-$10
Financing Activities
Debt Repay.$15$0$29$0
Stock Issued$33$42$0$90
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$160$93-$0$100
Financing Cash Flow$209$135$29$190
Forex Effect$0$0$0$0
Net Chg. in Cash$45$13-$41$131
Supplemental Information
Beg. Cash$138$125$166$35
End Cash$184$138$125$166
Free Cash Flow-$115-$65-$71-$59